Unintended Consequences of mHealth Interactive Voice Messages Promoting Contraceptive Use After Menstrual Regulation in Bangladesh: Intimate Partner Violence Results From a Randomized Controlled Trial.
Journal
Global health, science and practice
ISSN: 2169-575X
Titre abrégé: Glob Health Sci Pract
Pays: United States
ID NLM: 101624414
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
02
01
2019
accepted:
21
05
2019
entrez:
28
9
2019
pubmed:
29
9
2019
medline:
16
4
2020
Statut:
epublish
Résumé
Mobile phones for health (mHealth) hold promise for delivering behavioral interventions. We evaluated the effect of automated interactive voice messages promoting contraceptive use with a focus on long-acting reversible contraceptives (LARCs) among women in Bangladesh who had undergone menstrual regulation (MR), a procedure to "regulate the menstrual cycle when menstruation is absent for a short duration." We recruited MR clients from 41 public- and private-sector clinics immediately after MR. Eligibility criteria included having a personal mobile phone and consenting to receive messages about family planning by phone. We randomized participants remotely to an intervention group that received at least 11 voice messages about contraception over 4 months or to a control group (no messages). The primary outcome was LARC use at 4 months. Adverse events measured included experience of intimate partner violence (IPV). Researchers recruiting participants and 1 analyst were blinded to allocation groups. All analyses were intention to treat. The trial is registered with ClinicalTrials.gov (NCT02579785). Between December 2015 and March 2016, 485 women were allocated to the intervention group and 484 to the control group. We completed follow-up on 389 intervention and 383 control participants. Forty-eight (12%) participants in the intervention group and 59 (15%) in the control group reported using a LARC method at 4 months (adjusted odds ratio [aOR] using multiple imputation=0.95; 95% confidence interval [CI]=0.49 to 1.83; The intervention did not increase LARC use but had an unintended consequence of increasing self-reported IPV. Researchers and health program designers should consider possible negative impacts when designing and evaluating mHealth and other reproductive health interventions. IPV must be measured using closed questions naming acts of violence.
Sections du résumé
BACKGROUND
Mobile phones for health (mHealth) hold promise for delivering behavioral interventions. We evaluated the effect of automated interactive voice messages promoting contraceptive use with a focus on long-acting reversible contraceptives (LARCs) among women in Bangladesh who had undergone menstrual regulation (MR), a procedure to "regulate the menstrual cycle when menstruation is absent for a short duration."
METHODS
We recruited MR clients from 41 public- and private-sector clinics immediately after MR. Eligibility criteria included having a personal mobile phone and consenting to receive messages about family planning by phone. We randomized participants remotely to an intervention group that received at least 11 voice messages about contraception over 4 months or to a control group (no messages). The primary outcome was LARC use at 4 months. Adverse events measured included experience of intimate partner violence (IPV). Researchers recruiting participants and 1 analyst were blinded to allocation groups. All analyses were intention to treat. The trial is registered with ClinicalTrials.gov (NCT02579785).
RESULTS
Between December 2015 and March 2016, 485 women were allocated to the intervention group and 484 to the control group. We completed follow-up on 389 intervention and 383 control participants. Forty-eight (12%) participants in the intervention group and 59 (15%) in the control group reported using a LARC method at 4 months (adjusted odds ratio [aOR] using multiple imputation=0.95; 95% confidence interval [CI]=0.49 to 1.83;
CONCLUSIONS
The intervention did not increase LARC use but had an unintended consequence of increasing self-reported IPV. Researchers and health program designers should consider possible negative impacts when designing and evaluating mHealth and other reproductive health interventions. IPV must be measured using closed questions naming acts of violence.
Identifiants
pubmed: 31558596
pii: GHSP-D-19-00015
doi: 10.9745/GHSP-D-19-00015
pmc: PMC6816818
doi:
Banques de données
ClinicalTrials.gov
['NCT02579785']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
386-403Informations de copyright
© Reiss et al.
Références
Reprod Health. 2016 Jan 05;13:1
pubmed: 26728505
BMC Public Health. 2017 Oct 3;17(1):769
pubmed: 28974209
JMIR Form Res. 2017 Oct 27;1(1):e4
pubmed: 30684398
Contraception. 2017 Jan;95(1):90-97
pubmed: 27421767
Reprod Health. 2018 May 8;15(1):75
pubmed: 29739429
Int Perspect Sex Reprod Health. 2017 Mar 21;43(1):1-11
pubmed: 28930621
Am J Public Health. 2016 Sep;106(S1):S117-S124
pubmed: 27689478
J Epidemiol Community Health. 2015 Jan;69(1):95-8
pubmed: 25403381
BMJ Open. 2017 Nov 3;7(11):e017604
pubmed: 29101138
BMJ. 1999 Jul 17;319(7203):185
pubmed: 10406763
Obstet Gynecol. 2012 Jan;119(1):14-20
pubmed: 22143257
Am J Public Health. 2017 Feb;107(2):298-305
pubmed: 27997236
J Womens Health (Larchmt). 2008 May;17(4):579-84
pubmed: 18447762
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD009756
pubmed: 22419345
Bull World Health Organ. 2015 Dec 1;93(12):842-50A
pubmed: 26668436
PLoS One. 2016 May 04;11(5):e0154664
pubmed: 27144393
Contracept Reprod Med. 2017 May 1;2:16
pubmed: 29201421
AIDS Behav. 2017 Nov;21(11):3172-3181
pubmed: 28831618
Cochrane Database Syst Rev. 2015 Jun 26;(6):CD011159
pubmed: 26115146
Contraception. 2014 Sep;90(3):226-33
pubmed: 24850188
JMIR Mhealth Uhealth. 2016 Apr 15;4(2):e26
pubmed: 27083784
J Adolesc Health. 2015 Jul;57(1):100-6
pubmed: 26002432
Obstet Gynecol. 2011 May;117(5):1105-13
pubmed: 21508749
Int J Gynaecol Obstet. 2013 Nov;123 Suppl 1:e38-42
pubmed: 23992622
PLoS Med. 2013;10(1):e1001362
pubmed: 23349621
Health Technol Assess. 2016 Jul;20(57):1-82
pubmed: 27483185
Int J Gynaecol Obstet. 2016 Jul;134(1):93-8
pubmed: 27126905
Reprod Health. 2018 Feb 13;15(1):28
pubmed: 29433506
Int J Equity Health. 2013 Oct 16;12:85
pubmed: 24131553
Obstet Gynecol. 2010 Sep;116(3):633-40
pubmed: 20733446
Cochrane Database Syst Rev. 2013 Oct 26;(10):CD004317
pubmed: 24163097
Stud Fam Plann. 1999 Mar;30(1):54-66
pubmed: 10216896
Contraception. 2008 Sep;78(3):197-200
pubmed: 18692608
Stud Fam Plann. 2001 Sep;32(3):189-213
pubmed: 11677692
World Dev. 2018 Jan;101:284-292
pubmed: 29371749
Int J Gynaecol Obstet. 2013 Jan;120(1):3-9
pubmed: 22959631
Mhealth. 2018 May 21;4:14
pubmed: 29963559
BJOG. 2018 Nov;125(12):1620-1629
pubmed: 29924912